Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$7.87 CAD
Change Today -0.28 / -3.44%
Volume 27.1K
RX On Other Exchanges
Symbol
Exchange
OTC US
Venture
As of 3:59 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Open
C$8.40
Previous Close
C$8.15
Day High
C$8.40
Day Low
C$7.71
52 Week High
09/19/14 - C$12.82
52 Week Low
05/9/14 - C$5.01
Market Cap
109.2M
Average Volume 10 Days
26.5K
EPS TTM
C$0.22
Shares Outstanding
13.9M
EX-Date
--
P/E TM
35.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, engages in the marketing of pharmaceutical products in Canada. It is also involved in manufacturing and marketing non-chemical bio and health-friendly insecticides worldwide. The company markets FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; and FeraMAX Powder, an oral iron supplement. It also offers Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, and rectoscopies; and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, BioSyent Inc. manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$200.7K
Chief Financial Officer and Vice President
Total Annual Compensation: C$126.6K
Vice President of Biosyent Pharma Inc.
Total Annual Compensation: C$120.8K
Compensation as of Fiscal Year 2013.

biosyent inc (RX) Key Developments

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM

BioSyent Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 09:30 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada. Speakers: René C. Goehrum, Chairman, Chief Executive Officer and President.

BioSyent Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

BioSyent Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of CAD 3,058,503 against CAD 2,142,835 a year ago. EBITDA was CAD 1,056,576 against CAD 615,563 a year ago. Net income before tax was CAD 1,068,563 against CAD 619,124 a year ago. Net income after tax was CAD 753,199 against CAD 555,543 a year ago. For the year, the company reported revenues of CAD 12,211,127 against CAD 7,799,426 a year ago. EBITDA was CAD 4,299,963 against CAD 2,487,461 a year ago. Net income before tax was CAD 4,326,735 against CAD 2,452,840 a year ago. Net income after tax was CAD 3,154,079 against CAD 1,928,028 a year ago. 2014 Fully Diluted EPS of CAD 0.22 increased by 69% versus CAD 0.13 in 2013.

BioSyent Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

BioSyent Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s total sales were $3,632,128, were 56% higher compared to $2,328,064 in the prior year period. Net income before tax was $1,350,645, which is 67% higher than $808,749 in third quarter of 2013. Net income after tax increased by 64% from $609,749 in third quarter of 2013 to $1,000,654 in third quarter of 2014. Basic & diluted earnings per share was $0.07 against $0.04 a year ago. For the nine months, the company’s total sales were $9,152,624 were 62% higher than the prior year period. Net income before tax was $3,258,172 or 78% higher than the corresponding prior year period. Net income after tax was $2,400,880 or 75% higher than the corresponding prior year period. Diluted EPS was $0.17 against $0.09 in corresponding prior year period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$7.87 CAD -0.28

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies
 

Industry Analysis

RX

Industry Average

Valuation RX Industry Range
Price/Earnings 35.4x
Price/Sales 8.5x
Price/Book 13.2x
Price/Cash Flow 34.2x
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit www.biosyent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.